{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:09:36Z","timestamp":1790539776676,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Hunan key research and development program-key research and development projects in the field of social development","award":["2017SK2143"],"award-info":[{"award-number":["2017SK2143"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11255-019-02365-1","type":"journal-article","created":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T10:02:53Z","timestamp":1577872973000},"page":"399-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The therapeutic effect of dendritic cells expressing indoleamine 2,3-dioxygenase (IDO) on an IgA nephropathy mouse model"],"prefix":"10.1007","volume":"52","author":[{"given":"Kanghan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,1]]},"reference":[{"issue":"Suppl 1","key":"2365_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000481636","volume":"47","author":"RA Lafayette","year":"2018","unstructured":"Lafayette RA, Kelepouris E (2018) Immunoglobulin a nephropathy: advances in understanding of pathogenesis and treatment. Am J Nephrol 47(Suppl 1):43\u201352","journal-title":"Am J Nephrol"},{"issue":"Suppl 4","key":"2365_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/nep.13453","volume":"23","author":"YM Zhang","year":"2018","unstructured":"Zhang YM, Zhang H (2018) Update on treatment of immunoglobulin A nephropathy. Nephrology (Carlton) 23(Suppl 4):62\u201367","journal-title":"Nephrology (Carlton)"},{"key":"2365_CR3","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1159\/000495818","volume":"43","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhang Y, Liu D, Tan X, Tang X, Zhang F, Xia M, Chen G, He L, Zhou L, Zhu X, Liu H (2018) Prediction of ESRD in IgA nephropathy patients from an asian cohort: a random forest model. Kidney Blood Press Res 43:1852\u20131864","journal-title":"Kidney Blood Press Res"},{"key":"2365_CR4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.2215\/CJN.13701217","volume":"13","author":"M Shi","year":"2018","unstructured":"Shi M, Ouyang Y, Yang M, Yang M, Zhang X, Huang W, Wang W, Wang Z, Zhang W, Chen X, Pan X, Ren H, Chen N, Xie J (2018) IgA Nephropathy susceptibility loci and disease progression. Clin J Am Soc Nephrol 13:1330\u20131338","journal-title":"Clin J Am Soc Nephrol"},{"key":"2365_CR5","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1093\/ndt\/gft399","volume":"28","author":"H Takechi","year":"2013","unstructured":"Takechi H, Oda T, Hotta O, Yamamoto K, Oshima N, Matsunobu T, Shiotani A, Nagura H, Shimazaki H, Tamai S, Sakurai Y, Kumagai H (2013) Clinical and immunological implications of increase in CD208+ dendritic cells in tonsils of patients with immunoglobulin A nephropathy. Nephrol Dial Transp 28:3004\u20133013","journal-title":"Nephrol Dial Transp"},{"key":"2365_CR6","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/ndt\/gfm595","volume":"23","author":"JW Eijgenraam","year":"2008","unstructured":"Eijgenraam JW, Reinartz SM, Kamerling SW, van Ham VJ, Zuidwijk K, van Drunen CM, Daha MR, Fokkens WJ, van Kooten C (2008) Immuno-histological analysis of dendritic cells in nasal biopsies of IgA nephropathy patients. Nephrol Dial Transp 23:612\u2013620","journal-title":"Nephrol Dial Transp"},{"key":"2365_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clim.2007.11.003","volume":"126","author":"T Goto","year":"2008","unstructured":"Goto T, Bandoh N, Yoshizaki T, Nozawa H, Takahara M, Ueda S, Hayashi T, Harabuchi Y (2008) Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy. Clin Immunol 126:260\u2013269","journal-title":"Clin Immunol"},{"key":"2365_CR8","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1159\/000332032","volume":"119","author":"E Noessner","year":"2011","unstructured":"Noessner E, Lindenmeyer M, Nelson PJ, Segerer S (2011) Dendritic cells in human renal inflammation\u2013Part II. Nephron Exp Nephrol 119:e91\u201398","journal-title":"Nephron Exp Nephrol"},{"key":"2365_CR9","doi-asserted-by":"publisher","first-page":"6440","DOI":"10.4049\/jimmunol.174.10.6440","volume":"174","author":"SH Kim","year":"2005","unstructured":"Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, Mi Z, Watkins SC, Gambotto A, Robbins PD (2005) Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 174:6440\u20136448","journal-title":"J Immunol"},{"key":"2365_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ymthe.2005.09.015","volume":"13","author":"SH Kim","year":"2006","unstructured":"Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, Robbins PD (2006) Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther 13:289\u2013300","journal-title":"Mol Ther"},{"key":"2365_CR11","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.4049\/jimmunol.179.4.2242","volume":"179","author":"SH Kim","year":"2007","unstructured":"Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD (2007) Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J Immunol 179:2242\u20132249","journal-title":"J Immunol"},{"key":"2365_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1172\/JCI21583","volume":"114","author":"DH Munn","year":"2004","unstructured":"Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280\u2013290","journal-title":"J Clin Invest"},{"key":"2365_CR13","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/eji.200636690","volume":"37","author":"AK Manlapat","year":"2007","unstructured":"Manlapat AK, Kahler DJ, Chandler PR, Munn DH, Mellor AL (2007) Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. Eur J Immunol 37:1064\u20131071","journal-title":"Eur J Immunol"},{"key":"2365_CR14","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.4049\/jimmunol.175.9.5601","volume":"175","author":"AL Mellor","year":"2005","unstructured":"Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH (2005) Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 175:5601\u20135605","journal-title":"J Immunol"},{"key":"2365_CR15","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.biocel.2007.01.004","volume":"39","author":"NJ King","year":"2007","unstructured":"King NJ, Thomas SR (2007) Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 39:2167\u20132172","journal-title":"Int J Biochem Cell Biol"},{"key":"2365_CR16","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/blood-2006-11-056010","volume":"110","author":"SW Tas","year":"2007","unstructured":"Tas SW, Vervoordeldonk MJ, Hajji N, Schuitemaker JH, van der Sluijs KF, May MJ, Ghosh S, Kapsenberg ML, Tak PP, de Jong EC (2007) Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood 110:1540\u20131549","journal-title":"Blood"},{"key":"2365_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm1563","volume":"13","author":"U Grohmann","year":"2007","unstructured":"Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna ML, Ayroldi E, Nocentini G, Boon L, Bistoni F, Fioretti MC, Romani L, Riccardi C, Puccetti P (2007) Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 13:579\u2013586","journal-title":"Nat Med"},{"key":"2365_CR18","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/art.24446","volume":"60","author":"G Criado","year":"2009","unstructured":"Criado G, Simelyte E, Inglis JJ, Essex D, Williams RO (2009) Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1\/Th17 cells in the joint in collagen-induced arthritis. Arthritis Rheum 60:1342\u20131351","journal-title":"Arthritis Rheum"},{"key":"2365_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2741\/e414","volume":"4","author":"DH Munn","year":"2012","unstructured":"Munn DH (2012) Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed) 4:734\u2013745","journal-title":"Front Biosci (Elite Ed)"},{"key":"2365_CR20","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.2337\/db06-1727","volume":"56","author":"A Ueno","year":"2007","unstructured":"Ueno A, Cho S, Cheng L, Wang J, Hou S, Nakano H, Santamaria P, Yang Y (2007) Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes 56:1686\u20131693","journal-title":"Diabetes"},{"key":"2365_CR21","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1182\/blood-2008-12-195354","volume":"113","author":"MD Sharma","year":"2009","unstructured":"Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH (2009) Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113:6102\u20136111","journal-title":"Blood"},{"key":"2365_CR22","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1172\/JCI31911","volume":"117","author":"MD Sharma","year":"2007","unstructured":"Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117:2570\u20132582","journal-title":"J Clin Invest"},{"key":"2365_CR23","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.4049\/jimmunol.176.11.6752","volume":"176","author":"F Fallarino","year":"2006","unstructured":"Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176:6752\u20136761","journal-title":"J Immunol"},{"key":"2365_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.24229","volume":"60","author":"NR Bianco","year":"2009","unstructured":"Bianco NR, Kim SH, Ruffner MA, Robbins PD (2009) Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 60:380\u2013389","journal-title":"Arthritis Rheum"},{"key":"2365_CR25","first-page":"4867","volume":"17","author":"H Wu","year":"2018","unstructured":"Wu H, Gong J, Liu Y (2018) Indoleamine 2, 3-dioxygenase regulation of immune response (Review). Mol Med Rep 17:4867\u20134873","journal-title":"Mol Med Rep"},{"key":"2365_CR26","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3109\/08820139.2012.676122","volume":"41","author":"JL Harden","year":"2012","unstructured":"Harden JL, Egilmez NK (2012) Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest 41:738\u2013764","journal-title":"Immunol Invest"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02365-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02365-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02365-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:22:22Z","timestamp":1609374142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02365-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2365"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02365-1","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"assertion":[{"value":"11 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}